Mercury Laboratories Limited (BOM:538964)

Market Cap	1.01B
Revenue (ttm)	765.60M
Net Income (ttm)	37.71M
Shares Out	1.20M
EPS (ttm)	31.41
PE Ratio	26.90
Forward PE	n/a
Dividend	3.50 (0.41%)
Ex-Dividend Date	Aug 6, 2025

Volume	31
Average Volume	149
Open	843.70
Previous Close	843.70
Day's Range	843.70 - 843.70
52-Week Range	736.00 - 1,190.00
Beta	0.57
RSI	47.56
Earnings Date	Aug 7, 2025

About Mercury Laboratories

Mercury Laboratories Limited engages in manufacturing, selling, exporting, and dealing in various pharmaceutical drugs and medicines for mother and child healthcare in India and internationally. The company offers analgesic, anti-inflammatory, anti-pyretic, anthelmintic, antibiotic, anti-coagulant, anti-platelet, bleeding agent, anti-fungal, anti-hypertensive, anti-malarial, cardiovascular system, central nervous system, eye, gastro-intestinal system, hypoglycemic/anti-diabetic, multivitamin, protein supplement, respiratory system, anti-allergi...

• Industry: Pharmaceutical Preparations
• Founded: 1962
• Employees: 503
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 538964

Financial Performance

In 2024, Mercury Laboratories's revenue was 751.01 million, a decrease of -0.61% compared to the previous year's 755.59 million. Earnings were 31.45 million, a decrease of -44.38%.